Epione Medical Corporation

Fake Botox Use Rampant Despite FDA Warnings

In the past year, the FDA has issued five warnings to U.S. medical practitioners regarding the purchase and sale of counterfeit Botox. Simon Ourian, M.D., Medical Director of Epione Beverly Hills, a leading provider of Botox, expresses shock at the extent of the problem.

 

Beverly Hills, CA -- (ReleaseWire) -- 01/21/2013 -- According to the U.S. Food and Drug Administration, Canadian medical supplier Canada Drugs has been linked to the sale and distribution of fake Botox, as well as Levitra and Viagra, and the acne treatment drug Accutane (go to: goo.gl/dSUCE). A copy of the letter sent by the FDA to the physicians it determined received unapproved Botox from Canada Drugs can be found here (or go to: goo.gl/WC3fX). Authorities recently seized over $10.5 million worth of various counterfeit drugs (go to: goo.gl/D5R5A).

In addition, the supplier, its subsidiaries and related businesses have been ordered to stop marketing their fake Botox and other products to American practitioners and to shut down over 4,100 pharmaceutical websites (go to: goo.gl/dSUCE). The FDA’s action was part of Internet Action Week, a global effort involving international law enforcement and regulatory agencies from about 100 countries.

As of December 19, 2012 the Food and Drug Administration has issued a warning to more than 350 medical practices that they have received doses of the drug commonly known as Botox that may be contaminated or otherwise unsafe. “Frankly, I’m shocked at the extent of the problem,” says Simon Ourian, M.D., Medical Director of Epione Beverly Hills. “I never expected to see any of my colleagues in Beverly Hills on the FDA's list, but there they were.”

Please check here to ensure that your doctor is not among those implicated. If your doctor is not listed at the above site but you suspect that they are using counterfeit treatments, contact the FDA's Department of Criminal Investigations.

For more information about this issue please check here.